Company intelligence / Profile preview
Amphista Therapeutics
Cambridge / Granta Park, England/Cambridgeshire, United Kingdomamphista.com ↗
- Ownership
- Private
- Employees
- ~125
- Development stage
- Preclinical
01
Overview
Amphista has demonstrated differentiated mechanisms of action for its TPD assets in preclinical studies, including novel approaches to BRD9 degradation. The company has achieved discovery milestones in partnerships with major pharma companies but has not yet reported human clinical trial results.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Targeted protein degradation (TPD) using small molecule bifunctional "targeted glues" and degraders
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Bristol Myers Squibb ($30M upfront + up to $1.25B milestones)Merck Healthcare (€39M upfront/R&D + up to €893.5M milestones)
Beyond the preview
Go deeper on Amphista Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amphista Therapeutics.